![Nadim Ahmed](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nadim Ahmed
Vorstandsvorsitzender bei
CULLINAN THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.05.2026
Profil
Nadim Ahmed is currently President, Chief Executive Officer & Director at Cullinan Mica Corp., Cullinan Pearl Corp., and Cullinan Therapeutics, Inc. He is also a Director at Family Promise and will be a Director at Disc Medicine, Inc. starting in 2025.
Formerly, Mr. Ahmed was President, Chief Executive Officer & Director at Cullinan Oncology LLC.
From 2019 to 2021, served as President-Hematology at Bristol Myers Squibb Co. From 2010 to 2019, was President-Global Hematology & Oncology at Celgene Corp.
From 1998 to 2010, worked as Senior Marketing Director-Hematologic Oncology at GlaxoSmithKline LLC.
Education includes undergraduate studies at University College London and graduate studies at Loughborough University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2026 | 135’921 ( 0.23% ) | 2 Mio $ | 31.05.2026 |
Aktive Positionen von Nadim Ahmed
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Vorstandsvorsitzender | 18.10.2021 |
| DISC MEDICINE, INC. | Direktor/Vorstandsmitglied | 14.07.2025 |
Family Promise
 Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Direktor/Vorstandsmitglied | - |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Vorstandsvorsitzender | - |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Nadim Ahmed
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2021 |
| CELGENE | Corporate Officer/Principal | 01.11.2019 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01.03.2010 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Vorstandsvorsitzender | - |
Ausbildung von Nadim Ahmed
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
61
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
 Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
 Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
 Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
